Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

Wong, 2008, Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies, J Thromb Haemost, 6, 820, 10.1111/j.1538-7836.2008.02939.x

Geerts, 2008, Prevention of venous thromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines (8th edn), Chest, 133, 381S, 10.1378/chest.08-0656

Eriksson, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N Engl J Med, 358, 2765, 10.1056/NEJMoa0800374

Kakkar, 2008, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, Lancet, 372, 31, 10.1016/S0140-6736(08)60880-6

Lassen, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement, N Engl J Med, 358, 2776, 10.1056/NEJMoa076016

Turpie, 2009, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial, Lancet, 373, 1673, 10.1016/S0140-6736(09)60734-0

Eriksson, 2007, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, J Thromb Haemost, 5, 2178, 10.1111/j.1538-7836.2007.02748.x

Eriksson, 2007, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised double-blind, non-inferiority trial, Lancet, 370, 949, 10.1016/S0140-6736(07)61445-7

Ginsberg, 2009, Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery, J Arthroplasty, 24, 1, 10.1016/j.arth.2008.01.132

Lassen, 2009, Apixaban or enoxaparin for thromboprophylaxis after knee replacement, N Engl J Med, 361, 594, 10.1056/NEJMoa0810773

Rabinov, 1972, Roentgen diagnosis of deep vein thrombosis, Arch Surg, 104, 134, 10.1001/archsurg.1972.04180020014004

Schulman, 2005, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, J Thromb Haemost, 3, 692, 10.1111/j.1538-7836.2005.01204.x

Lassen, 2007, The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement, J Thromb Haemost, 5, 2368, 10.1111/j.1538-7836.2007.02764.x

Yanagawa, 1994, Mantel-Haenszel-type tests for testing equivalence or more than equivalence in comparative clinical trials, Biometrics, 50, 859, 10.2307/2532800

Colwell, 2005, Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty, J Bone Joint Surg Am, 87, 2169, 10.2106/JBJS.D.02184

Agnelli, 2009, Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran, Thromb Res, 123, 488, 10.1016/j.thromres.2008.02.017

Friedman, 2008, Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty, Curr Med Res Opin, 24, 87, 10.1185/030079907X242746

Turpie, 2002, Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies, Arch Intern Med, 162, 1833, 10.1001/archinte.162.16.1833

Eriksson, 2009, Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement, J Bone Joint Surg Br, 91, 636, 10.1302/0301-620X.91B5.21691